Abstract
Schizophrenia is a serious mental disorder that affects up to 1% of the population
worldwide. Traditional models of schizophrenia have emphasized
dopaminergic dysfunction. Over the last 20 years, however, limitations
of the dopamine model have become increasingly apparent, necessitating
development of alternative models. Glutamatergic models are based upon
the observation that the psychotomimetic agents such as phencyclidine
(PCP) and ketamine induce psychotic symptoms and neurocognitive
disturbances similar to those of schizophrenia by blocking
neurotransmission at N-methyl-D-aspartate (NMDA)-type glutamate
receptors. Because glutamate/NMDA receptors are located throughout the
brain, glutamatergic models predict widespread cortical dysfunction with
particular involvement of NMDA receptors throughout the brain. Further,
NMDA receptors are located on brain circuits that regulate dopamine
release, suggesting that dopaminergic deficits in schizophrenia may also
be secondary to underlying glutamatergic dysfunction. Agents that
stimulate NMDA receptor-mediated neurotransmission, including
glycine-site agonists and glycine transport inhibitors, have shown
encouraging results in preclinical studies and are currently undergoing
clinical development. Encouraging results have been observed as well
with agents such as metabotropic 2/3 agonists that decrease resting
glutamate levels, reversing potential disruption in firing patterns
within prefrontal cortex and possibly other brain regions. Overall,
these findings suggest that glutamatergic theories may lead to new
conceptualizations and treatment approaches that would not be possible
based upon dopaminergic models alone.
Source: http://www.ncbi.nlm.nih.gov/pubmed/20686195